- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04207125
Improving ImmunoSuppression Adherence After Liver or Kidney Transplantation (ISALK)
Improving ImmunoSuppression Adherence After Liver or Kidney Transplantation -a Randomized Controlled Single Centre Trial
Indication: liver (LT) or kidney Transplantation (KT)
Objectives: to measure medication adherence in liver or kidney transplant patients with and without multilevel intervention programme over time
Trial Design: prospective, single-centre, randomized controlled study
Population: patients (male/female/diverse) between 18 and 90 years of age scheduled for LT or KT
Sample Size:
75 control patients (standard of care) 75 patients in treatment group (participation in multilevel intervention programme)
Statistical Analysis: The data will be analysed descriptively; continuous variables will be summarized using mean ± SD (standard deviation) or median, minimum and maximum and categorical data will be summarized using absolute and relative frequencies. For the primary outcome (Adherence to the immunosuppressive regime measured by BAASIS) and further categorical variables, differences between the groups will be assessed by the Pearson Chi-square test or Fisher's exact test. Group differences for continuous parameters will be assessed by the two-sample T-test or Mann-Whitney-U-test as appropriate.
Trial Duration and Dates: November 2019-October 2021
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Organ transplantation is the best option for patients with chronic organ failure. After kidney (KT) or liver transplantations (LT), immunosuppressive medications have to be taken to avoid rejection. Lifelong adherence, the extent to which the patients behaviour matches the agreed upon prescribers recommendations, to immunosuppressive drugs is important to prevent graft failure (Pabst et al., 2015). The consequent immunosuppression intake and regular physician visits are important factors for a long transplant survival (Nöhre et al., 2018).
A high rate of immunosuppressive medication non-adherence and its impact on post-transplant graft function indicate a need for adherence enhancing interventions (De Bleser et al., 2011).
Non-adherence is linked to poor post-transplant outcomes including late acute rejection and graft loss (De Geest S. et al 2011; Dew MA et al 2008). Dew et al. concluded from a meta- analysis of 147 transplantation studies that nonadherence in renal allograft recipients was highest among solid organ transplant recipients, reaching 36 cases per 100 patients per year (Dew et al., 2007). Detection of adherence can be obtained by objective direct measures (observation that medication was taken) or indirect and subjective measures like self-reporting. The indirect measures include serum drug levels, biological markers and electronic monitoring. Adherence is a dynamic process with the need to be repetitive over time. The monitoring should be incorporated into the routine clinical management of all organ recipients. A recent study showed that combining self-reporting, assay and clinicians report yielded the highest sensitivity (72%) and specificity (42%) when compared to electronic monitoring (Low et al., 2019). Some new evidence suggest that moving from twice-daily to once-daily dosing of the immunosuppressive regimen, the calcineurin inhibitor, show indifferent prevalence rates with increased adherence or not improving the adherence (Lehner et al., 2018; Fellström et al., 2018).The aim of our study is to test the efficacy of such a multilevel education and psychosomatic intervention programme for improving medication adherence in patients after LT or KT.
- Primary Objective and Primary Endpoint The primary endpoint is the assessment of patient adherence using a validated version of the Basel Assessment of Adherence to Immunosuppressive Medication Scale (BAASIS) questionnaire.
- Secondary Objectives and Secondary Endpoints Secondary endpoints include the influence of the multilevel intervention programme on the coefficient of variation (CV%) of Tacrolimus (TAC), clinical outcomes including incidence of infections, acute rejection, liver and kidney values, death, graft loss, hospital readmission during the study period, side effects, number of trough level controls necessary during first 6 months, and achievement of TAC target concentrations.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jolana Wagner-Skacel, MD
- Phone Number: 004331638583036
- Email: jolana.wagner-skacel@medunigraz.at
Study Contact Backup
- Name: Nadja Fink, BSc
- Email: nadja.fink@klinikum-graz.at
Study Locations
-
-
-
Graz, Austria, 8036
- Recruiting
- Medical University of Graz, Klin. Abteilung für Transplantationschirurgie
-
Contact:
- Judith Kahn, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients (male/female) listed for LT and KT
- Ability of subject to understand character and individual consequences of the trial
- Fluent in speaking the German language
- Written informed consent must be available before enrolment in the trial
- Basis immunosuppression with Tacrolimus
Exclusion Criteria:
- Patients < 18 or > 90 years
- Pregnant or lactating women
- Refusal to participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Without multilevel intervention
patients after liver or kidney transplantation / standard care
|
|
ACTIVE_COMPARATOR: With multilevel intervention
patients after liver or kidney transplantation / multilevel intervention program
|
Part 1: Educational Training and Mentoring After transferring the patient from the intensive care unit to the transplant surgery unit, nurses are planning a nursing diagnosis called "therapy recommendations and coping strategies, effective implementation". 3 days after the transfer, nurses start to give information twice a day (morning and evening) about the medication, which the patients are currently taking. The nurse is also handing out a folder, which contains information about the multilevel intervention programme. Individual Treatment Approach Patients, who seem to be non-adherent during their outpatient follow-ups, are contacted through the co-investigators for a one-to-one session. The content of this session is to promote patients engagement in self-management of their chronic illness. The goal of the treatment is to improve the individual's ability to manage symptoms, treatments, physical and psychosocial consequences and lifestyle changes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
self-rating of adherence
Time Frame: 6 months
|
Basler Assessment of Adherence to Immunosuppressive Medication Scale (BAASIS) The Basler assessment was developed to assess adherence to immunosuppressive drugs in adult transplant recipients.
It follows the newly published taxonomy of medication adherence.
This self-reported interview consists of three quantifiable phases: initiation, implementation and persistence.
Five Items assess the implementation dimension and one assesses the persistence.
An optional item assesses initiation.
Responses to four questions are given on a 6-point scale ranging from zero (never) to five (every day) (Dobbels et al., 2010).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Coefficient of Variation (CV%) of Tacrolimus
Time Frame: 6 months
|
6 months
|
|
Occurrence of infection episodes
Time Frame: 6 months
|
6 months
|
|
Occurrence of rejection episodes
Time Frame: 6 months
|
Biopsy-proven acute rejection
|
6 months
|
Rejection therapy
Time Frame: 6 months
|
Administered rejection therapies
|
6 months
|
Occurrence of side effects
Time Frame: 6 months
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
influencing psychodynamic factors
Time Frame: 6 months
|
Survey on distress: Global Symptom Load Level of Personality Functioning The Relationship Structures questionnaire of the Experiences in Close Relationships-Revised (ECR-RS) Scale that is designed to assess attachment dimensions in multiple contexts will be used (Frayley, Heffernan, & Vicary et al., 2011).
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Peter Schemmer, Prof., Medical University of Graz
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 32-062 ex 19/20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adherence Intervention Post Transplantation
-
Johns Hopkins UniversityCompletedLiver Transplantation | Medication Adherence | Kidney TransplantationUnited States
-
University of SaskatchewanVancouver Coastal Health; Saskatchewan Health Authority - Regina Area; Southern... and other collaboratorsRecruitingMedication Adherence | Kidney TransplantationUnited States, Canada
-
Imperial College LondonCompletedAdherence, Medication | Transplantation, KidneyUnited Kingdom
-
McGill University Health Centre/Research Institute...The Hospital for Sick Children; Children's Hospital of Philadelphia; Washington... and other collaboratorsCompletedMedication Adherence | Kidney TransplantationUnited States, Canada
-
McGill University Health Centre/Research Institute...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedMedication Adherence | Kidney TransplantationCanada, United States
-
Johns Hopkins UniversityWithdrawnLiver Transplantation | Medication AdherenceUnited States
-
Imperial College LondonCompletedMedication Adherence | Kidney TransplantationUnited Kingdom
-
Akdeniz UniversityRecruitingMedication Adherence | Kidney Transplantation | Treatment Adherence | Motivational Interviewing | Patient Outcome Assessment | Self-Management | AdultTurkey
-
VA Boston Healthcare SystemCenter for Integration of Medicine & Innovative Technology; New England Veterans...UnknownRate of Post-discharge Medication AdherenceUnited States
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Coordenação de Aperfeiçoamento...CompletedMetabolic and Inflammatory Variables Post Intervention | Composition and Function of the Gut Microbiota Post InterventionBrazil
Clinical Trials on Multilevel psychotherapeutic intervention programme
-
Adaliene Versiani M. FerreiraConselho Nacional de Desenvolvimento Científico e Tecnológico; Fundacion MAPFRERecruiting
-
University of BernSwiss National Science FoundationUnknownColorectal CancerSwitzerland
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
William Paterson University of New JerseyCompletedDiet Modification | Cancer Prevention | Vegetable IntakeUnited States
-
Temple UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Tuğba AşkanNot yet recruiting
-
San Diego State UniversityNot yet recruitingVaccine Hesitancy
-
The University of Texas Health Science Center at...National Institute on Aging (NIA)Not yet recruitingType 2 DiabetesUnited States
-
Rhode Island HospitalEmory University; Boston Medical Center; University of Mississippi Medical CenterEnrolling by invitationHIV/AIDS | Medication AdherenceUnited States
-
Rhode Island HospitalNot yet recruiting